Analysis of biological potency and chemical consistency of Ethyl Acetate Purified FAHF-2 for treatment of food allergy

Abstract

Carolina at Chapel H. RATIONALE: Though peanut sublingual immunotherapy (SLIT) is a potentially efficacious treatment for patients with peanut allergy, its use is limited by adverse events, which are understudied. METHODS: We conducted a retrospective pooled cohort analysis from two peanut SLIT trials to determine characteristics and rates of AEs. We abstracted in-home AEs from daily symptom diaries. We characterized events that were at least possibly related to SLIT dosing. Bivariate analyses were performed to determine differences in rates of AEs by season and other patient characteristics. RESULTS: Of 101 participants (mean age 6.9 years) enrolled in 2 SLIT trials (mean duration 4.6 years), 86% experienced a total of 6377 possiblyor likely-related AEs associated with SLIT dosing; 14 participants (14%) accounted for 75% of all AEs. Ninety-six percent of AEs were mild; 2 reactions (0.03%) were severe. Systemic reactions accounted for 3.7% of AEs in 34% of participants. Most AEs involved transient oropharyngeal symptoms (84%), which occurred in 69% of participants. Those with AR had more frequent AEs, with increased AEs in June, July, and August (1247 in those with AR vs. 772 in those without AR, p<0.001). No epinephrine was administered. Antihistamines were used in 4% of AEs by 43% of participants. CONCLUSIONS: While peanut SLIT is associated with frequent AEs, nearly all are graded mild and most symptoms are limited to the oropharynx. Those with allergic rhinitis are at increased risk for AEs, particularly during the summer months and possibly implicates crossreactive pollen sensitization as one mechanism for AEs in peanut SLIT.

Traditional Chinese medicine for food allergy and eczema

“…Peanut-specific IgE fell 70%. 27 EBF2 IgE inhibition was associated with IgE heavy-chain suppression.…”

The Roles and Mechanisms of Gut Microbiota in Food Allergy

“…Using murine models of peanut allergy, Maskey et al assessed the chemical stability and biological potency of FAHF-2, BF2, and EBF2. The three formulas all inhibited IgE production, with EBF2 being the most potent, suggesting that EBF2 is a clinically promising treatment for peanut allergy [151]. In addition to FAHF-2, formula-3 and a traditional Japanese herbal medicine Kakkonto were also shown to ameliorate FA [152,153].…”